17
55
2
↑17
↓55
—2
Evidence suggests Melatonin maydecreaseTumor growth.
63 studies (74 claims)
Moderate consensus
Typical effective dose 1.5 (1.5–1.5) mgacross 1 dosed study
Study Claims
| Intervention | Direction | Endpoint | Type | Population | Dosage | Title |
|---|---|---|---|---|---|---|
| 100 µM melatonin and 5 mM vitamin C added to IVF medium | Increases - improves the growth of the embryo up to the blastocyst stage | growth of the embryo up to the blastocyst stage | HumanAnimal | oocytes and putative embryos from Gonadotropin-releasing hormone (GnRH) and Human Chorionic Gonadotropin (HMG) -stimulated mice | — | Assessment of developmental rate of mouse embryos yielded from in vitro fertilization of the oocyte with treatment of melatonin and vitamin C simultaneously. |
| melatonin | Increases - stimulating | bone growth | Human | — | Not specified. | Melatonin, bone regulation and the ubiquitin-proteasome connection: A review.cited 48× |
| melatonin | Decreases - inhibits | breast cancer cell growth | Human | — | Not specified | Melatonin, an inhibitory agent in breast cancer.cited 68× |
| Melatonin | Decreases - display anti-proliferative effects on | breast cancer growth and proliferation | Human | — | Not specified | Circadian Rhythm and Concentration of Melatonin in Breast Cancer Patients.cited 11× |
| melatonin | Decreases - inhibitory effects on | cancer cell growth | Human | — | Not specified | Melatonin: Current evidence on protective and therapeutic roles in gynecological diseases.cited 4× |
| melatonin (MLT) | Decreases - decreasing | cancer cell growth | Human | — | Not specified | Melatonin and cisplatin co-treatment against cancer: A mechanistic review of their synergistic effects and melatonin's protective actions.cited 2× |
| melatonin | Decreases - restrains | cancer development and growth | Human | — | Not specified | Melatonin, a Full Service Anti-Cancer Agent: Inhibition of Initiation, Progression and Metastasis.cited 310× |
| melatonin | No effect - influence | cancer growth | HumanMolecular | — | Not specified | Update on the role of melatonin in the prevention of cancer tumorigenesis and in the management of cancer correlates, such as sleep-wake and mood disturbances: review and remarks.cited 47× |
| Melatonin | Decreases - has oncostatic effects | cancer growth | Molecular | various oncological cells | Not specified | Melatonin and its ubiquitous anticancer effects. |
| Melatonin | Decreases - has oncostatic effects | cancer growth | Molecular | various oncological cells | Not specified | Melatonin and its ubiquitous anticancer effects. |
| melatonin | Decreases - inhibiting cell growth | cell growth | Human | — | — | Melatonin and 5-fluorouracil combination chemotherapy: opportunities and efficacy in cancer therapy.cited 36× |
| Melatonin | Decreases - reduced cell growth | cell growth | Molecular | — | Not specified (low and high concentrations mentioned, but exact amounts not provided). | Regulation of cancer cell glucose metabolism is determinant for cancer cell fate after melatonin administration.cited 24× |
| Melatonin | Decreases - present numerous antitumor effects | cell growth | Molecular | — | Not specified (low and high concentrations mentioned, but exact amounts not provided). | Regulation of cancer cell glucose metabolism is determinant for cancer cell fate after melatonin administration.cited 24× |
| melatonin | Increases - caused enhanced | cell growth | Animal | primary BALB/c mouse chondrocytes | — | Circadian production of melatonin in cartilage modifies rhythmic gene expression. |
| melatonin (N-acetyl-5-metoxy-tryptamine) (MLT) | Decreases - limiting or reversing | changes occurring during cancer development and growth | Molecular | — | Not provided. | A Review on Melatonin's Effects in Cancer: Potential Mechanisms. |
| melatonin (N-acetyl-5-metoxy-tryptamine) (MLT) | Decreases - limiting or reversing | changes occurring during cancer development and growth | Molecular | — | Not provided. | A Review on Melatonin's Effects in Cancer: Potential Mechanisms. |
| melatonin (N-acetyl-5-metoxy-tryptamine) (MLT) | Decreases - suppress | growth of various tumours | Molecular | in vivo and in vitro | Not provided. | A Review on Melatonin's Effects in Cancer: Potential Mechanisms. |
| melatonin (N-acetyl-5-metoxy-tryptamine) (MLT) | Decreases - suppress | growth of various tumours | Molecular | in vivo and in vitro | Not provided. | A Review on Melatonin's Effects in Cancer: Potential Mechanisms. |
| melatonin | Decreases - inhibit | development and/or growth of various experimental animal tumors and some human cell lines | HumanMolecular | experimental animal tumors and some human cell lines in vitro | Not specified | Melatonin, a natural programmed cell death inducer in cancer.cited 52× |
| Melatonin | Decreases - reversing the up-regulated amounts of | different transcription factors, growth factors, inflammatory cytokines, protein kinases, and other oncogenic agents | Human | — | Not specified | Melatonin as a Promising Agent for Cancer Treatment: Insights into its Effects on the Wnt/beta-catenin Signaling Pathway.cited 3× |
| melatonin | Decreases - reduced | ELT3 tumor growth | HumanAnimalMolecular | xenograft and orthotopic uterine tumor mice models | — | Melatonin activates cell death programs for the suppression of uterine leiomyoma cell proliferation. |
| melatonin | Decreases - reduced | growth of uterine leiomyoma ELT3 cells | HumanAnimalMolecular | uterine leiomyoma ELT3 cells | — | Melatonin activates cell death programs for the suppression of uterine leiomyoma cell proliferation. |
| melatonin | Decreases - plays a role in suppression | uterine leiomyoma growth | HumanAnimalMolecular | — | — | Melatonin activates cell death programs for the suppression of uterine leiomyoma cell proliferation. |
| melatonin | No effect - modulation of | estrogen-regulated cell proliferation, invasiveness and expression of proteins, growth factors and proto-oncogenes (hTERT, p53, p21, TGFβ, E-cadherin, etc.) | Human | cells expressing ERα | Physiologic doses (specific amounts not provided) | Breast cancer therapy based on melatonin.cited 29× |
| melatonin | Increases - activating | gene expression of insulin-like growth factor-1 | Human | — | Not specified | The effects of melatonin on neurohormonal regulation in cardiac cachexia: A mechanistic review.cited 6× |
| melatonin | Increases - acts as a cue for | growth and development | Human | Plasmodium falciparum | Not mentioned | Malaria, anti malarial drugs and the role of melatonin.cited 4× |
| melatonin | Increases - stimulates | growth and development of P. falciparum | HumanAnimalMolecular | in vitro | High doses (specific amounts not stated) and melatonin antagonist luzindole used. | Malaria: therapeutic implications of melatonin.cited 43× |
| Melatonin | Decreases - inhibits | growth and invasive capacity of colon cancer cells | HumanMolecular | in vitro | — | Gender-related invasion differences associated with mRNA expression levels of melatonin membrane receptors in colorectal cancer. |
| melatonin | Decreases - has been observed to suppress | growth of cancer cells | Human | in vitro and in vivo models | — | The rationale for treating uveal melanoma with adjuvant melatonin: a review of the literature.cited 14× |
| Melatonin | Decreases - suppress | growth of carcinogen-induced mammary tumors | AnimalMolecular | rats | — | In vitro and in vivo antitumor activity of melatonin receptor agonists. |
| melatonin | Decreases - attenuate | increased levels of nuclear factor kappa B, tumor necrosis factor alpha, transforming growth factor beta 1, SMAD2, interleukin (IL)-4, IL-4 receptor-a1 (IL4ra1), and IL-1 beta | Human | — | Not specified | The role of melatonin on radiation-induced pneumonitis and lung fibrosis: A systematic review.cited 21× |
| melatonin | Increases - induces production | insulin growth factor | HumanMolecular | — | Not specified | The role of melatonin in diabetes: therapeutic implications. |
| melatonin | Increases - induces production | insulin growth factor | HumanMolecular | — | Not specified | The role of melatonin in diabetes: therapeutic implications. |
| melatonin | Decreases - minimize or prevent | intrauterine growth restriction | Human | pediatric age group | Not specified | Melatonin treatment in fetal and neonatal diseases.cited 15× |
| melatonin | Decreases - is effective in suppressing | neoplastic growth | Human | — | Not specified | Melatonin, immune function and cancer.cited 70× |
| melatonin | Increases - applied on the skin as a photoprotective, anti-aging, or hair growth-promoting agent | skin photoprotection, anti-aging, hair growth | Human | — | Not specified | Clinical Studies Using Topical Melatonin.cited 8× |
| topical melatonin | No effect - do not provide a clear demonstration of the efficacy of | hair growth-promoting | Human | — | Not specified | Clinical Studies Using Topical Melatonin.cited 8× |
| melatonin | Decreases - reduce the frequency or severity | stillborn fetus, recurrent fetal loss, preeclampsia, fetal growth retardation, premature delivery, and fetal teratology | Human | pregnancy | Not specified | Melatonin-mediated actions and circadian functions that improve implantation, fetal health and pregnancy outcome.cited 7× |
| Melatonin | Decreases - inhibits | the expression of vascular endothelial growth factors | HumanMolecular | — | Not specified | The Potential Oncostatic Effects of Melatonin against Prostate Cancer. |
| Melatonin | Decreases - inhibits | the expression of vascular endothelial growth factors | HumanMolecular | — | Not specified | The Potential Oncostatic Effects of Melatonin against Prostate Cancer. |
| melatonin | Decreases - has oncostatic and antitumoral properties | tumor growth | Human | — | Not specified | Potential use of melatonin in skin cancer treatment: A review of current biological evidence.cited 32× |
| melatonin | Decreases - acts as an anti-inflammatory and reactive oxygen species inducer agent which suppresses | tumor growth | Human | — | Not specified | Potential use of melatonin in skin cancer treatment: A review of current biological evidence.cited 32× |
| melatonin | Decreases - exerts oncostatic effects | tumor growth | Human | — | Not specified | The emergence of melatonin in oncology: Focus on colorectal cancer.cited 48× |
| melatonin | Decreases - reduction | tumor growth | Molecular | — | Not specified | Melatonin in Cancer Treatment: Current Knowledge and Future Opportunities.cited 117× |
| melatonin | Decreases - interferes with | tumor growth | Molecular | — | Not specified. | Melatonin modulates tumor metabolism and mitigates metastasis.cited 10× |
| Melatonin | Decreases - inhibited | tumor growth | HumanAnimalMolecular | xenograft mouse models | — | Quantum mechanics insights into melatonin and analogs binding to melatonin MT |
| melatonin | Decreases - combat | tumor growth | HumanMolecular | — | Not specified | Melatonin as a multifunctional anti-cancer molecule: Implications in gastric cancer.cited 38× |
| melatonin | Decreases - regulation of these mediators by melatonin mitigates | tumor growth | Molecular | — | Not specified | Therapeutic targets of cancer drugs: Modulation by melatonin.cited 23× |
| melatonin | Decreases - has been sparingly investigated to counteract | tumor growth | HumanMolecular | osteosarcoma cell lines | Not specified | Molecular and Cellular Mechanisms of Melatonin in Osteosarcoma.cited 35× |
| Melatonin | Decreases - inhibited | tumor growth | AnimalMolecular | ascitic HCC mouse models using H22 cells | Not specified | Melatonin suppresses PD-L1 expression and exerts antitumor activity in hepatocellular carcinoma. |
| melatonin | Decreases - inhibition | vascular endothelial growth factor (VEGF) | Molecular | — | Not specified | Melatonin as an angiogenesis inhibitor to combat cancer: Mechanistic evidence.cited 80× |
| melatonin | Decreases - decreased | xenograft CCA tumor growth | HumanAnimalMolecular | nude mice | — | Melatonin exerts by an autocrine loop antiproliferative effects in cholangiocarcinoma: its synthesis is reduced favoring cholangiocarcinoma growth. |
| melatonin and vitamin D | Decreases - indicate potential for tumor growth inhibition | tumor growth | Human | patients with cancer | Not specified | Melatonin and vitamin D as potential synergistic adjuvants for cancer therapy (Review).cited 5× |
| melatonin use | Increases - improved | scalp hair growth | Human | melatonin users | 0.0033% or 0.1% topical solution once daily; 1.5 mg oral melatonin twice daily. | Melatonin and the Human Hair Follicle.cited 9× |
| melatonin use | Increases - facilitate | scalp hair growth | Human | men with AGA | 0.0033% or 0.1% topical solution once daily; 1.5 mg oral melatonin twice daily. | Melatonin and the Human Hair Follicle.cited 9× |
| exogenous melatonin (MT) | Decreases - alleviated | growth damage caused by PEG-simulated drought stress | Animal | Camellia hainanica seedlings | 0, 50, 100, 150, 200, and 250 μmol/L applied through irrigation. | Influence of Exogenous Melatonin on the Physiological Traits of Camellia hainanica Seedlings Under Polyethylene Glycol-Induced Drought Stress. |
| exogenous melatonin at appropriate concentrations (0.02, 0.1 mmol·L-1) under salt stress | Increases - could promote | plant growth | Animal | 4-year-old Ginkgo biloba seedlings | Melatonin solution (0, 0.02, 0.1, 0.5 mmol·L-1) applied via leaf spray and soil watering | Effects of exogenous melatonin on the osmotic regulation and antioxidant capacity of Ginkgo biloba seedlings under salt stress.cited 2× |
| melatonin-coated lactoferrin-chitosan nanoparticles (ETP-CS-LF-MLT-NPs) | Decreases - inhibited | Proteus mirabilis growth | HumanAnimalMolecular | in vitro | Not specified in the abstract. | Fabrication of lactoferrin-chitosan-etoposide nanoparticles with melatonin via carbodiimide coupling: In-vitro & in-vivo evaluation for colon cancer.cited 2× |
| andrographolide (AGP) and melatonin (MLT) | Decreases - lead to | CSC growth inhibition | Molecular | colon cancer stem cells (CSCs) | Not specified | Targeting mitochondrial ribosomal protein expression by andrographolide and melatonin for colon cancer treatment.cited 1× |
| melatonin antagonist, luzindole | Decreases - effectively reduced | growth and differentiation of malarial parasites | HumanAnimal | malarial parasites | Not specified | Melatonin effects on Plasmodium life cycle: new avenues for therapeutic approach.cited 6× |
| melatonin (MLT) alone | No effect - was not beneficial to | growth and pigment accumulation | Animal | Dunaliella bardawil | 200 μg/mL, 300 μg/mL, and 400 μg/mL MLT | A strategy to promote carotenoids production in Dunaliella bardawil by melatonin combined with photoinduction.cited 6× |
| Melatonin signaling via melatonin receptor type 1 (MT1) | Decreases - inhibits | tumor growth | AnimalMolecular | xenograft mouse models | — | Disruption of Melatonin Signaling Leads to Lipids Accumulation in the Liver of Melatonin Proficient Mice. |
| melatonin and insulin coadministration | Decreases - caused greater reductions | circulating tumor necrosis factor-α, tumor growth factor-β1, interleukin (IL)-1β, and IL-6 levels | Animal | diabetic rats | — | Coadministration of Melatonin and Insulin Improves Diabetes-Induced Impairment of Rat Kidney Function. |
| melatonin pre-treated MSCs (MSCMel) | Decreases - delayed | tumor growth | AnimalMolecular | orthotopic and subcutaneous GBM xenograft mouse models | Not specified | Glioblastoma progression is hindered by melatonin-primed mesenchymal stromal cells through dynamic intracellular and extracellular reorganizations. |